Pancreatic neoplasm – Diagnostics – Overview of Information and Clinical Research

Diagnosing pancreatic cancer is one of the most challenging tasks in medicine, as early signs are often absent or easily mistaken for other conditions. By the time symptoms appear, the disease has frequently progressed to advanced stages, making timely detection critical yet difficult to achieve.

Introduction: Who Should Undergo Diagnostics

Pancreatic cancer begins quietly, without obvious warning signs in its earliest and most treatable stages. This silence makes determining who should seek diagnostic testing particularly important. Understanding when to pursue evaluation can make a meaningful difference in catching the disease earlier.

People who experience certain symptoms should consider seeking medical evaluation promptly. These symptoms include yellowing of the skin and whites of the eyes, a condition called jaundice that occurs when the pancreas tumor blocks bile ducts. Dark-colored urine and light or pale-colored stools often accompany jaundice. Pain in the upper belly area or middle back, especially when it becomes persistent or worsens after eating or when lying down, deserves medical attention. Unexpected weight loss without trying to lose weight, along with loss of appetite, can signal a problem requiring investigation.^[1]^[2]

Other concerning signs include constant fatigue that doesn’t improve with rest, nausea and vomiting that persist, feelings of bloating or gas that won’t go away, and blood clots that form without obvious injury. Some people develop diabetes seemingly out of nowhere or notice their existing diabetes suddenly becomes harder to control. These changes happen because the pancreas, which produces insulin, is being affected by the growing tumor.^[2]^[6]

⚠️ Important

Many people with pancreatic cancer do not notice any symptoms until the disease has grown or spread to other organs. Some individuals report having vague symptoms for up to one year before receiving a diagnosis. Because early pancreatic cancer rarely causes noticeable problems, regular check-ups and paying attention to unusual changes in your body become especially important.

Certain individuals face higher risk and may benefit from earlier or more vigilant monitoring. Those with a family history of pancreatic cancer, especially if multiple relatives have had the disease, should discuss screening options with their doctor. People with inherited genetic conditions like Lynch syndrome, Peutz-Jeghers syndrome, or mutations in the BRCA1, BRCA2, PALB2, or ATM genes carry increased risk. Current or former cigarette smokers, people with chronic inflammation of the pancreas called pancreatitis, individuals with long-standing diabetes, and those carrying excess body weight all face elevated chances of developing pancreatic cancer.^[4]^[6]

Anyone experiencing unexplained symptoms that persist for more than a few weeks should not hesitate to contact their healthcare provider. While these symptoms can result from many conditions far less serious than cancer, only proper medical evaluation can determine the cause. Early investigation offers the best chance of identifying pancreatic cancer when treatment options remain most effective.

Diagnostic Methods for Identifying Pancreatic Cancer

Diagnosing pancreatic cancer requires multiple types of tests working together to build a complete picture. The pancreas sits deep in the abdomen, tucked behind the stomach and surrounded by other organs, making it difficult to examine directly. Doctors cannot simply feel a pancreatic tumor during a physical examination in most cases. Instead, they rely on sophisticated imaging techniques, laboratory analysis, and tissue sampling to reach a diagnosis.

Imaging Tests

Several types of imaging tests help doctors visualize the pancreas and detect abnormal growths. A computed tomography scan, commonly called a CT scan, uses X-rays taken from multiple angles to create detailed cross-sectional images of the body. For pancreatic cancer, a special type called a helical CT scan provides particularly clear views of the pancreas and surrounding blood vessels. This test helps determine if a tumor exists, how large it is, and whether it has spread to nearby structures or distant organs.^[10]^[17]

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves instead of radiation to create detailed pictures of soft tissues. MRI scans excel at showing the pancreas itself and can help distinguish between different types of pancreatic masses. Doctors often use MRI when they need additional information beyond what CT scans provide.^[10]^[17]

Ultrasound testing bounces sound waves off internal organs to create images. A regular ultrasound performed through the abdominal wall often cannot see the pancreas clearly because other organs block the view. However, endoscopic ultrasonography overcomes this limitation by placing a tiny ultrasound device on the end of a thin, flexible tube that passes through the mouth and into the stomach. From this close vantage point, the ultrasound can capture detailed images of the pancreas. This technique also allows doctors to take tissue samples using a needle guided by the ultrasound images.^[10]^[17]

Minimally Invasive Procedures

When imaging suggests a pancreatic tumor but more information is needed, doctors may perform procedures that allow direct visualization. Laparoscopy involves making small incisions in the abdomen and inserting a thin tube with a camera attached. This allows surgeons to see the pancreas and surrounding organs directly, checking for cancer spread that imaging might have missed. Laparoscopic ultrasound combines this direct viewing with ultrasound examination performed inside the abdomen. These techniques help avoid unnecessary major surgery by revealing whether a tumor can be safely removed before making larger surgical incisions.^[17]

Another procedure called endoscopic retrograde cholangiopancreatography, or ERCP for short, uses an endoscope passed through the mouth into the small intestine. Doctors inject dye into the pancreatic ducts and bile ducts, then take X-rays to reveal blockages or narrowing that might indicate cancer. During ERCP, doctors can also place small tubes called stents to keep blocked ducts open, relieving jaundice even before final diagnosis or treatment.^[10]

Laboratory Tests

Blood tests provide important clues about pancreatic cancer, though no single blood test can definitively diagnose the disease. When jaundice occurs, blood tests showing elevated levels of a substance called bilirubin confirm that bile isn’t flowing normally. Tests of liver function can indicate whether the liver is being affected by a blocked bile duct or cancer spread.

A blood test measuring CA 19-9, also called cancer antigen 19-9, often shows elevated levels in people with pancreatic cancer. However, this marker has limitations because not all pancreatic cancers produce elevated CA 19-9, and some non-cancerous conditions can also raise these levels. Because of its lack of specificity, CA 19-9 testing alone cannot diagnose pancreatic cancer. Doctors primarily use CA 19-9 levels to monitor how cancer responds to treatment or to detect cancer recurrence after treatment ends.^[17]

Tissue Biopsy

The most definitive way to diagnose cancer involves examining actual cells from the suspicious area under a microscope. This process, called a biopsy, removes a small sample of tissue for laboratory analysis. For pancreatic masses, biopsies are often performed using a needle inserted through the skin into the tumor, guided by CT scan or ultrasound images. Alternatively, as mentioned earlier, doctors can obtain tissue samples during endoscopic ultrasonography by passing a needle through the endoscope directly into the pancreatic mass.

Laboratory specialists called pathologists examine the biopsied tissue to determine whether cancer cells are present and, if so, what type of cancer it is. Most pancreatic cancers are a type called adenocarcinoma, which begins in the cells lining the pancreatic ducts. About 90 to 95 percent of pancreatic cancers fall into this category. Other rarer types include acinar cell carcinoma and various forms of cystic tumors. Identifying the specific cancer type helps guide treatment decisions.^[5]^[6]

⚠️ Important

Pancreatic cancer proves notoriously difficult to detect early because tumors in early stages do not appear on most imaging tests. The pancreas’s location deep in the body, hidden behind other organs, makes visualization challenging. By the time a tumor grows large enough to cause symptoms or become visible on scans, the cancer has often already spread beyond the pancreas. This reality makes any persistent, unexplained symptoms worth investigating promptly.

Staging Evaluation

Once pancreatic cancer is confirmed, additional testing determines the cancer’s stage, meaning how far it has spread. Staging influences treatment choices significantly. Doctors use imaging tests to check whether cancer has spread to lymph nodes, nearby blood vessels, the liver, or other distant organs. In some cases, surgeons perform peritoneal cytology, examining fluid from the abdominal cavity under a microscope to detect cancer cells that have spread there. Finding cancer cells in this fluid usually means the cancer cannot be completely removed with surgery.^[17]

The staging process classifies pancreatic cancer as resectable (can be surgically removed), borderline resectable (might be removable with surgery), locally advanced (has invaded nearby structures too extensively for surgery), or metastatic (has spread to distant organs). Only about 20 percent of people with pancreatic cancer have disease that can potentially be removed completely with surgery at the time of diagnosis.^[4]^[14]

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments for pancreatic cancer, offering access to innovative approaches not yet widely available. However, enrolling in a clinical trial requires meeting specific criteria established by researchers designing each study. Diagnostic tests play a crucial role in determining whether a patient qualifies for participation in a particular trial.

Most clinical trials establish strict eligibility requirements based on cancer stage and extent. Researchers conducting trials for resectable pancreatic cancer need imaging tests demonstrating that the tumor hasn’t invaded major blood vessels and appears removable through surgery. Conversely, trials testing treatments for advanced disease require documentation showing cancer spread to distant organs or involvement of critical blood vessels. Imaging tests like CT scans, MRI scans, and PET scans provide this essential staging information.^[17]

Tissue analysis becomes particularly important for clinical trials testing targeted therapies or immunotherapies. Many newer treatments work by targeting specific genetic mutations or molecular characteristics present in some cancers but not others. Before enrolling in such trials, patients must undergo biomarker testing, also called molecular profiling or genetic testing. Laboratories analyze tumor tissue obtained from biopsies to identify particular genetic changes, protein markers, or other molecular features. If a patient’s tumor carries the specific markers targeted by a trial’s experimental treatment, they may qualify for enrollment. Without these markers, the treatment being studied likely wouldn’t help them.^[2]

Some clinical trials require testing for inherited genetic mutations in addition to tumor characteristics. Mutations in genes like BRCA1, BRCA2, PALB2, or ATM can influence how pancreatic cancer develops and responds to certain treatments. Patients may need blood tests checking for these inherited mutations to qualify for trials targeting cancers with these genetic profiles.^[6]

Clinical trials also set standards for patients’ overall health and organ function. Blood tests measuring liver function, kidney function, and blood cell counts help determine whether a patient’s body can safely handle experimental treatments. Tests showing how well major organs function ensure that patients enrolled can tolerate the treatment being studied without excessive risk. Similarly, tests measuring tumor markers like CA 19-9 at the start of a trial provide baseline measurements that researchers will track throughout the study to assess treatment effectiveness.

Understanding treatment history matters for trial eligibility as well. Some trials specifically seek patients who have never received treatment, while others require that participants have already tried and progressed through standard treatments. Medical records documenting previous therapies, along with recent imaging showing how the cancer responded or failed to respond, determine qualification for different trial types.

The diagnostic workup for clinical trial enrollment often involves more extensive testing than routine clinical care. Researchers need detailed information to ensure patient safety, maintain study integrity, and accurately measure outcomes. Patients interested in clinical trials should discuss the required diagnostic procedures with their medical team to understand what testing will be necessary for potential enrollment.

Prognosis and Survival Rate

Prognosis

The outlook for pancreatic cancer depends heavily on several factors that influence how the disease progresses and responds to treatment. The most important factor affecting prognosis is whether the tumor can be completely removed with surgery. Only surgical resection offers the possibility of cure, but unfortunately, only about 20 percent of patients present with disease that appears removable at diagnosis. Even among those who undergo successful surgery, the cancer frequently returns because microscopic disease that was undetectable during surgery later grows into visible tumors.^[4]^[14]

Whether cancer has spread to lymph nodes significantly impacts prognosis. Patients whose cancer remains confined to the pancreas without lymph node involvement generally have better outcomes than those with lymph node spread. The extent of spread to distant organs also critically influences outcomes, with cancer confined to the pancreas having better prognosis than disease that has reached the liver, lungs, or other distant sites.^[17]

The tumor’s location within the pancreas plays a role as well. Cancers in the head of the pancreas often cause symptoms like jaundice earlier, potentially leading to earlier detection compared to cancers in the body or tail of the pancreas. Earlier detection sometimes translates to more treatment options and improved outcomes. A patient’s overall health status, age, and ability to tolerate treatments also influence prognosis. Those in better general health with well-functioning organs can typically handle more aggressive treatments that may improve outcomes.^[14]

Research shows that even at high-volume specialty medical centers, where outcomes tend to be better than average, disease recurrence remains a major problem. Studies examining patients who received chemotherapy and radiation before surgery found that after surgical removal of the pancreas tumor, cancer returned locally in the pancreas area in 11 to 25 percent of patients, spread to the liver in about 23 percent, and recurred with distant organ spread in 59 to 73 percent of cases. These statistics highlight that pancreatic cancer frequently involves microscopic spread too small to detect even with modern imaging and surgical techniques.^[14]

Survival Rate

Pancreatic cancer survival statistics paint a sobering picture, though outcomes vary considerably based on disease stage at diagnosis. The overall five-year survival rate for pancreatic cancer in the United States ranges from only 5 to 15 percent, with the overall survival rate across all stages standing at just 6 percent. This makes pancreatic cancer one of the deadliest cancer types. In fact, pancreatic cancer ranks as the fourth leading cause of cancer deaths in the United States despite being only the tenth most common cancer, reflecting its aggressive nature and poor survival outcomes.^[2]^[4]

Among patients with early-stage disease who undergo surgical resection at high-volume specialty centers, outcomes improve somewhat but remain challenging. Published data from major cancer centers indicate that 10 to 27 percent of patients with early-stage pancreatic cancer who had surgery survived at least five years. While these numbers represent better outcomes than the overall survival statistics, they still demonstrate that even with the best current treatments, the majority of patients do not survive long-term.^[14]

The difficulty of detecting pancreatic cancer early contributes significantly to poor survival rates. Because early-stage tumors rarely cause symptoms and don’t appear on routine imaging, most people receive their diagnosis only after the cancer has grown substantially or spread to other organs. By that point, surgical removal becomes impossible, and available treatments can only slow progression rather than cure the disease. The absence of effective screening tests for the general population means detection typically occurs late in the disease course.^[2]^[11]

Current trends indicate pancreatic cancer cases are increasing. Projections suggest that pancreatic cancer will become the second leading cause of cancer death in the United States by 2030. This expected rise makes ongoing research into better detection methods and more effective treatments critically important for improving future survival rates.^[2]

#1 Clinical Trials Search in Europe